Neurocrine study shows Ingrezza improved tardive dyskinesia symptoms
San Diego-based Neurocrine Biosciences, Inc. (NASDAQ:NBIX) recently published findings from its KINECT-PRO Phase 4 study demonstrating that Ingrezza (valbenazine) treatment improved symptoms for patients with tardive dyskinesia, according to a press release. The open-label study included 59 participants who received once-daily doses of 40 mg, 60 mg, or 80 mg of Ingrezza for up to 24 weeks.
Baseline data showed that 41% of patients had mild tardive dyskinesia, while 59% had moderate or severe symptoms. By Week 24, mean improvements in the Tardive Dyskinesia Impact Scale and Abnormal Involuntary Movement Scale were -8.0 and -6.8, respectively, both surpassing established minimal clinically important difference thresholds.
Approximately 58% of patients met the criteria for symptomatic remission, defined as a movement severity score of 0 or 1 in seven body regions assessed.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
